Labiotech.eu

News and Trends 19 Feb 2016

Biotech of the week: NZYTech, one of the biggest Portuguese Biotech companies

This week, we leave the cold of Norway and head South-West to warmer climates. Not Spain this time, we arrive in the capital of Portugal, Lisbon. This city has a nightlife that can rival Madrid, Castles looking onto beaches and is the location of our biotech of the week, NZYTech. City: Lisbon, Portugal Founded: 2008 Employees: 50 […]

February 19, 2016 - 1 minutemin - By Philip Hemme

bone therapeutics allob preob spine therapy medtech

News and Trends 18 Feb 2016

This Bone Cell Therapy Could Make it to a Shelf Near You

Bone Therapeutics (Belgium) is almost finished with the phase IIa trial for a Spinal cell therapy. The 12 people treated for degenerative bone conditions show no complications – a gold star for the safety check of this off-the-shelf product. This Belgian biotech is developing two different osteoblastic cell therapies, PREOB and ALLOB, to treat a variety of […]

February 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

jens nielsen novozymes chalmers nordisk novo cell factories

News and Trends 18 Feb 2016

This Pioneering Systems Biology Professor Received a €400K Prize from Novozymes

Jens Nielsen pioneered Systems Biology in Europe. His research efforts focus on transferring science research to industrial applications – to create a society independent of fossil fuels. He has now been awarded Novozymes Prize. Nielsen, a professor at Chalmers University of Technology in Gothenburg (Sweden), literally co-wrote the book on Metabolic Engineering back in 1998. During this period he […]

February 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

italy agriculture biotech fund crea cisgenesis gmo

News and Trends 18 Feb 2016

Italy Bets on Agriculture and Invests €21M in Sustainable-Biotech

Italian agriculture is booming with Innovation. To boost the creation of cutting-edge products and increase competition between businesses, €21M has been provided by the Italian government to fund sustainable biotechnology and research. The three-year plan focuses on the Council for Agricultural Research and Agricultural Economics Analysis (CREA), a specialized research centre in Rome which is collaborating with the […]

February 18, 2016 - 3 minutesmins - By Joachim Eeckhout

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

apogenix glioblastoma cancermark german apg101

News and Trends 17 Feb 2016

Brain Cancer Biomarker is a Magnet for Public Money in Germany

Apogenix (Germany) has been granted €3M for a personalized medicine to treat glioblastoma. It will also use this funding to develop a companion diagnostic test using a specific cancer biomarker, which other German biotechs are also attempting to do… This Heidelberg based-biotech (which we visited on our Labiotech tour of South Germany) is focused on the development of protein Immuno-Oncology therapeutics to treat […]

February 17, 2016 - 3 minutesmins - By Dani Bancroft

abbvie galapagos cystic fibrosis glpg1837

News and Trends 17 Feb 2016

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser… Galapagos is one of the most hotly-discussed Biotechs in Europe, with around 400 employees and historic IPOs on NASDAQ. It is partnered with several big Pharma, like Gilead, AbbVie, Servier (to develop […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Feb 2016

This Swiss Bioinformatics Start-Up is Simplifying NGS and Data Driven Medicine for Hospitals

As one of the most successful medical bioinformatics start-ups in Europe, Sophia Genetics (Switzerland) has now forged a partnership with a US nucleic acid synthesis company to facilitate the transition to Data Driven Medicine. This Swiss start-up led the way in European medical informatics when their software earned accreditation to store patient genomic data – a true […]

February 16, 2016 - 2 minutesmins - By Denise Neves Gameiro

clinical depression glasgow ets6103 e therapeutics

News and Trends 16 Feb 2016

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

I mean, Clinical depression is a tough indication for Biotech to tackle – particularly when facing off a ’55-year old’ generic (amitriptyline). But e-Therapeutics in Oxford (UK) has more to offer in its pipeline, despite this phase IIb failure in Glasgow. The trial’s aims were to determine whether ETS6103 was an antidepressant capable of treating the patients for […]

February 16, 2016 - 3 minutesmins - By Dani Bancroft

alpaca nejm purpura thrombocytopenia blood titan hercules

News and Trends 16 Feb 2016

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results. Ablynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with […]

February 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Feb 2016

The Only Real European Biotech Unicorns in 2016

Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting bigger and bigger, 146 companies while I’m writing this article (look at the full list on the Wall Street Journal). There is a very reduced number of Biotech unicorns worldwide and even less in Europe. There are actually only 3: […]

February 16, 2016 - 3 minutesmins - By Philip Hemme

4d pharma microbiome tucana ucc ibs cork

News and Trends 15 Feb 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

Have you ever heard of 4D pharma (UK)? Well, it’s become one of the biggest and cash-rich players in the European Microbiome scene. Perhaps the acquisition of this Irish Chronic disease spin-off will bring their name to the spotlight… 4D pharma in Leeds (England) acquired Tucana, a spin-off from the University College Cork (UCC), to complement its therapeutic platform […]

February 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biotech of the week: NZYTech, one of the biggest Portuguese Biotech companies

This Bone Cell Therapy Could Make it to a Shelf Near You

This Pioneering Systems Biology Professor Received a €400K Prize from Novozymes

Italy Bets on Agriculture and Invests €21M in Sustainable-Biotech

Cancer: World Best Ever CAR-T Results have Just been Disclosed

Brain Cancer Biomarker is a Magnet for Public Money in Germany

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

This Swiss Bioinformatics Start-Up is Simplifying NGS and Data Driven Medicine for Hospitals

Sorry Scotland, Phase II Trial for Clinical Depression Fails against 55-Year Old Generic

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

The Only Real European Biotech Unicorns in 2016

Europe’s Richest Microbiome Biotech Acquires Irish Start-up To Accelerate!

Subscribe to our newsletter to get the latest biotech news!